Former President of the College of Naturopathic Physicians of British Columbia Joins StillCanna’s Team

Vancouver, British Columbia – (PR Newswire) – Thursday, May 16, 2019 – StillCanna Inc. (CSE: STIL) (“STIL” or the “Company”) is pleased to announce that Dr. Brian Martin, ND has joined the StillCanna Team. Dr. Martin brings a wealth of knowledge and experience, including but not limited to:

  • 25 years practicing Naturopathic Medicine;
  • the formulation of innovative natural health products;
  • former President of the College of Naturopathic Physicians of British Columbia; and
  • Expert in Optimal Aging from the American Academy of Anti-Aging Medicine.

Dr. Martin will lead the Company’s consumer and Nutraceutical and Cosmeceutical product formulations with the goal of enhancing the natural capabilities of CBD and other therapeutic cannabinoids, including terpenes and other organic compounds. He will be the Company’s medical representative for industry research, speaking engagements and product formulations. Dr. Martin will evaluate the current Olimax product line and expects to formulate new CBD related products with a special focus on the expanding nutritional (food and beverages) and wellness marketplaces. Particular attention will be directed towards the female market, along with matters related to the improvement of quality of life, including products aiming to enhance energy, mood, memory, libido and athletic performance.

“Dr. Martin has dedicated his life to the proactive empowerment of the modern consumer, and has developed substantial practical experience and knowledge of the current health needs of both men and women” exclaimed Jason Dussault Chief Executive Officer of StillCanna. “We anticipate that his practical knowledge and capabilities will make StillCanna’s CBD products increasingly effective and metabolically friendly compared to other products currently available in the market. Dr. Martin will work with the Company part time for the next 2 quarters with an eye towards full time employment as we expand our product vision.”

“I have been very impressed with some of the proprietary techniques and technologies StillCanna has relating to the production and formulation of various CBD products,” stated Dr. Martin. “StillCanna’s vision of CBD in the wellness and the global Nutraceutical market is in line with the types of CBD products I envision. StillCanna’s CEO has strong branding and marketing skills which, coupled with my formulation skills, paints a very exciting picture.”

As partial compensation for the engagement of Dr. Martin, the Company will grant 200,000 incentive stock options to Dr. Martin with an exercise price equivalent to a 5% premium to the closing price of the Company’s common shares on the date of grant.

Further to its press release dated May 7, 2019, the Company has also issued 850,000 common shares to certain finders in connection with the acquisition of Olimax. As a result, an aggregate of 1,300,000 common shares have been issued to finders in connection with the acquisition of Olimax.

About StillCanna Inc.

StillCanna Inc. (CSE: STIL) www.StillCanna.com is a Canadian early-stage life sciences company focused on large scale CBD extraction in Europe.  The Company feels its proprietary intellectual property allows it to extract CBD at a lower cost. The Company has signed an initial extraction contract in Europe to be the exclusive extractor for Dragonfly BioSciences LLC, a United Kingdom-based supplier of CBD. The Company also recently completed the acquisition of Olimax NT SP. Z .O.O, which is expected to increase the Company’s market share in the European CBD industry.

 On Behalf of the Board,
Jason Dussault,
Chief Executive Officer and Director
Email: info@stillcanna.com
Phone: 604-239-0840

Cautionary Note Regarding Forward Looking Statements: This release includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws, including statements regarding the enhancement of the natural capabilities of CBD and other therapeutic cannabinoids, the formulation of new CBD related products, including products to enhance energy, mood, memory, libido and athletic performance, the increased effectiveness and metabolic friendliness of the Company’s products and the hiring of Dr. Martin as a full time employee of the Company. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should” or “would” occur. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including that the Company will be able to enhance the natural capabilities of CBD and other therapeutic cannabinoids, that the Company will be able to formulate new CBD related products, including products to enhance energy, mood, memory, libido and athletic performance, that the Company will be able to increase the effectiveness and metabolic friendliness of the its products and that the Company will be able to hire Dr. Martin as a full time employee of the Company. Although the Company considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect, and the forward-looking statements in this release are subject to numerous risks, uncertainties and other factors that may cause future results to differ materially from those expressed or implied in such forward-looking statements. Such risk factors may include, among others, that the Company will not be able to enhance the natural capabilities of CBD and other therapeutic cannabinoids, that the Company will not be able to formulate new CBD related products, including products to enhance energy, mood, memory, libido and athletic performance, that the Company will not be able to increase the effectiveness and metabolic friendliness of the its products and that the Company will not be able to hire Dr. Martin as a full time employee of the Company. Readers are cautioned not to place undue reliance on forward-looking statements. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not intend, and expressly disclaims any intention or obligation to, update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

Stillcanna Acquires Polish Hemp Producer and Receives the Proceeds of Its $24,365,000 Financing

Vancouver, British Columbia–(Newsfile Corp. – May 7, 2019) – STILLCANNA INC. (CSE: STIL) (“StillCanna” or the “Company”) the Company is pleased to announce that further to the Company’s press release dated March 18, 2019, the Company successfully acquired 100% of Olimax’s issued and outstanding shares.

The acquisition of Olimax provides Stillcanna with a vertically integrated licensed cultivator, extractor and formulator of CBD. One of Olimax’s many core strengths is its agriculture expertise with hemp.

The founders of Olimax Zofia Valber and Krystyna Bojeck have taken on the roles of VP Operations Poland and will oversee the day-to-day management of the Company’s Polish operations. With over 40 years combined experience in hemp products, their accomplishments include a patented microelement fertilizer and the germination and registration of an EU certified propriety varietal of high CBD content hemp. Zofia and Krystyna have decades of hemp production and product formulations along with degrees in agriculture and chemistry.

The Company is seeding its 1500 hectares of land in Poland with the Company’s proprietary hemp varietal and expects its harvest to be in early August.

“This acquisition uniquely positions Stillcanna in the supply chain of wholesale CBD in Europe,” pointed out Jason Dussault Chief Executive Officer of StillCanna, “there is global interest in sourcing a reliable flow of wholesale CBD in Europe and StillCanna is now in a position to address that global interest.”

The purchase price of Olimax consists of 24,000,000 common shares and $2,000,000 in cash. 20,064,000 of the 24,000,000 shares are subject to a contractual restriction on trading whereby 1/12 of the shares will be released from such contractual restriction every three months from the date of issuance and all of the shares are subject to a four-month and a day hold period from the date of issuance, in accordance with applicable Canadian securities laws.

As previously announced on April 25, 2019, the Company completed a financing of an aggregate of 21,187,587 subscription receipts at a price of $1.15 per subscription receipt for aggregate gross proceeds of approximately $24,365,000 with Canaccord Genuity Corp. as agent. The net proceeds of the financing were released to the Company in connection with the satisfaction of the escrow release conditions by the Company through its successful acquisition of Olimax. The subscription receipts automatically converted into one common share of the Company and one-half of one common share purchase warrant. Each warrant is exercisable to acquire one common share for a period of 12 months at an exercise price of $1.73.

The Company intends to use the net proceeds of the Offering to expand its CBD processing capacity at the Company’s facility in Romania, to build out Olimax’s CBD extraction facility and agricultural capabilities in Poland along with working capital and general corporate expenditures.

In connection with the acquisition of Olimax, the Company issued 450,000 common shares to certain finders. It also issued 700,000 common shares to certain consultants in exchange for financial advisory services.

ABOUT STILLCANNA INC.

StillCanna Inc. (CSE: STIL) (www.stillcanna.com) is a Canadian early-stage life sciences company focused on large-scale CBD extraction in Europe. Based on a proprietary process and intellectual property, the Company is forecasted to be one of the lowest-cost CBD extractors operating in Europe. The Company has signed an extraction contract to be the exclusive extractor for Dragonfly BioSciences LLC, a United Kingdom-based supplier of CBD. With the completion of the Olimax Transaction, StillCanna is one of the leading processors and providers of market-ready CBD in Europe.

On Behalf of the Board,

Joel Leonard,
Chief Financial Officer and Director
E-mail: joel@stillcanna.com
Phone: 778-838-3692

The CSE has not in any way passed upon the merits of and has neither approved nor disapproved the contents of this news release.

Cautionary Note Regarding Forward Looking Statements: This release includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws, including statements regarding the expected harvest date of the Company’s 1,500 hectares of land being in early August. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should” or “would” occur. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including that the cultivation of the Company’s hemp will be successful and the harvest date of the Company’s 1,500 hectares of land will be in early August as anticipated by management of the Company. Although the Company considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect, and the forward-looking statements in this release are subject to numerous risks, uncertainties and other factors that may cause future results to differ materially from those expressed or implied in such forward-looking statements. Such risk factors may include, among others, that the cultivation of the Company’s hemp will not be successful or will be delayed and the harvest date of the Company’s 1,500 hectares of land will not be in early August or at all. Readers are cautioned not to place undue reliance on forward-looking statements. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not intend, and expressly disclaims any intention or obligation to, update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

StillCanna Begins Hemp Initiative in Poland

Vancouver, British Columbia–(Newsfile Corp. – April 30, 2019) – StillCanna Inc. (CSE: STIL) (“STIL” or the “Company”) is pleased to announce it has begun its agricultural initiatives in Poland to farm over 1,500 hectares of its propriety high CBD content hemp varietal.

StillCanna has ordered and anticipates delivery in July of special harvesters and conveyors with proprietary dryers to make the harvest easy and efficient. The high-tech equipment is capable of speeds up to 15km per hour with a special four and a half meter wide cutting device. It’s estimated that the Company’s 2019 harvest will produce over 16 million grams of pure CBD. As our proprietary strain of hemp has a gestation period of 45 days, the Company is considering planting two crops on a number of its properties to increase its CBD production capabilities for 2020.

The Company anticipates breaking ground in May for its new CBD refinement facility in Poland, which is expected to cost approximately $6 million to complete its development. The facility is designed to have the capacity to initially produce up to 40 million grams of CBD annually with the ability to further build out the facility to increase production as necessary.

“Spring is an exciting time for global agriculture and StillCanna,” explained Jason Dussault, Chief Executive Officer of StillCanna. “The expansion of our EU footprint into Poland is yet another milestone in the implementation of our business initiatives. With over 20 years experience in hemp cultivation, we look forward to meeting the ever increasing demand for quality CBD from our fields and facilities.”

The Company also announces that it has engaged Native Ads Inc. to provide and manage a comprehensive digital media marketing campaign for the Company.

The Company has entered into an eight week programmatic digital advertising campaign for an approximate cost of one hundred thousand dollars for digital advertising, paid distribution, media buying and content creation. Neither Native Ads nor any of its directors and officers own any securities of the Company.

About StillCanna Inc.

StillCanna Inc. (CSE: STIL) www.stillcanna.com is a Canadian early-stage life sciences company focused on large scale CBD production in Europe. The company believes that its proprietary intellectual property allows it to extract CBD more efficiently and at a lower cost. The company has signed an initial extraction contract in Europe to be the exclusive extractor for Dragonfly BioSciences LLC, a United Kingdom-based supplier of CBD. Upon the completion of the Olimax transaction, StillCanna will be one of the largest processor and providers of market ready CBD in Europe.

On Behalf of the Board,
Joel Leonard,
Chief Financial Officer and Director
E-mail: joel@stillcanna.com

The CSE has not in any way passed upon the merits of and has neither approved nor disapproved the contents of this news release.

Cautionary Note Regarding Forward Looking Statements: This release includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws, including statements regarding the anticipated delivery in July of the harvesters and conveyors, the Company’s anticipated 2019 CBD yield of 16 million grams, the anticipated timeline of May for beginning construction of a CBD extraction facility in Poland, and the anticipated level of production at the planned CBD extraction facility in Poland and its anticipated cost. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should” or “would” occur. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including that the harvesters and conveyors will be delivered in July, the Company’s will have a 2019 CBD yield of 16 million grams, the construction of a CBD extraction facility in Poland will begin in May, and the level of production at the planned CBD extraction facility in Poland and its anticipated cost will be as anticipated by the Company’s management. Although the Company considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect, and the forward-looking statements in this release are subject to numerous risks, uncertainties and other factors that may cause future results to differ materially from those expressed or implied in such forward-looking statements. Such risk factors may include, among others, that the harvesters and conveyors will not be delivered in July, the Company’s will not have a 2019 CBD yield of 16 million grams, the construction of a CBD extraction facility in Poland will not begin in May or at all, and the level of production at the planned CBD extraction facility in Poland and its anticipated cost will not be as anticipated by the Company’s management. Readers are cautioned not to place undue reliance on forward-looking statements. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not intend, and expressly disclaims any intention or obligation to, update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

StillCanna Closes Oversubscribed Private Placement of Subscription Receipts for $24,365,000

Vancouver, British Columbia–(Newsfile Corp. – April 25, 2019) – STILLCANNA INC. (CSE: STIL) (“StillCanna” or the “Company”) the Company is pleased to announce that further to the Company’s press release on March 18, 2019, it closed its oversubscribed private placement (the “Offering“) offering of subscription receipts (“Subscription Receipts“) for aggregate gross proceeds of approximately $24,365,000. The Offering was led by Canaccord Genuity Corp. (the “Agent“).

“Investors in today’s cannabis landscape have many options available to them,” stated Jason Dussault, Chief Executive Officer of Stillcanna. “Their confidence and support of our Company through this financing is an attribute to the Company’s business model and vision. This financing gives the Company the financial means to meet the exciting opportunities it has fostered.”

The Company intends to use the net proceeds of the Offering to expand its CBD processing capacity at the Company’s facility in Romania, to build out Olimax’s CBD extraction facility and agricultural capabilities in Poland along with working capital and general corporate expenditures.

The Company issued 16,409,591 Subscription Receipts pursuant to the brokered portion of the Offering and 4,125,822 Subscription Receipts pursuant to the non-brokered portion of the Offering being an aggregate 21,187,587 Subscription Receipts at a price of $1.15 per Subscription Receipt (the “Issue Price“). Each Subscription Receipt entitles the holder thereof to receive, upon satisfaction of certain escrow release conditions (including the completion of the Olimax transaction previously announced on March 18, 2019) and without payment of any additional consideration or any further action on the part of each holder thereof, one unit of StillCanna (each a “Unit“). StillCanna anticipates closing the Olimax transaction within the first half of May, 2019. Each Unit will consist of one common share of the Company (“Common Share“) and one-half of one Common Share purchase warrant (each a “Warrant“). Each Warrant will be exercisable to acquire one Common Share for a period of 12 months from the date the escrow release conditions are satisfied at an exercise price of $1.73. If the escrow release conditions are not satisfied by June 30, 2019, the Subscription Receipts will be cancelled, and all proceeds from the brokered financing will be returned to subscribers.

All securities issued pursuant to the Financing will be subject to a four-month-and-one-day hold period from the closing date, in accordance with applicable Canadian securities laws.

As consideration for their services in connection with the Offering, the Agent was paid a commission equal to 7.0% of the gross proceeds of the brokered portion of the Offering and also received warrants (the “Compensation Warrants“) to acquire that number of Units which is equal to 7.0% of the aggregate number of Subscription Receipts sold under the brokered portion of the Offering. Each Compensation Warrant is exercisable at the Issue Price for a period of 12-months following the date the escrow release conditions are satisfied. The Agent also received an advisory fee of $384,628.68 and 334,460 advisory warrants (the “Advisory Warrants“) in connection with the Offering. Each Advisory Warrant is exercisable at the Issue Price for a period of 12-months following the date the escrow release conditions are satisfied.

ABOUT STILLCANNA INC.

StillCanna Inc. (CSE: STIL) (www.stillcanna.com) is a Canadian early-stage life sciences company focused on large-scale CBD extraction in Europe. Based on a proprietary process and intellectual property, the Company is forecasted to be one of the lowest-cost CBD extractors operating in Europe. The Company has signed an extraction contract to be the exclusive extractor for Dragonfly BioSciences LLC, a United Kingdom-based supplier of CBD. Upon the completion of the Olimax Transaction, StillCanna will be one of the leading processors and providers of market-ready CBD in Europe.

On Behalf of the Board,

Joel Leonard,
Chief Financial Officer and Director
E-mail: joel@stillcanna.com

The CSE has not in any way passed upon the merits of and has neither approved nor disapproved the contents of this news release.

Cautionary Note Regarding Forward Looking Statements: This release includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws, including the statement that the Olimax transaction is expected to closing within the first half of May, 2019. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should” or “would” occur. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including that the Olimax transaction will close as anticipated by management within the first half of May, 2019. Although the Company considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect, and the forward-looking statements in this release are subject to numerous risks, uncertainties and other factors that may cause future results to differ materially from those expressed or implied in such forward-looking statements. Such risk factors may include, among others, that the Olimax transaction will not close as anticipated by management within the first half of May, 2019 or at all. Readers are cautioned not to place undue reliance on forward-looking statements. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not intend, and expressly disclaims any intention or obligation to, update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

StillCanna Recruits Seasoned PhD to Manage Its Romanian Extraction Facility and Provides Update on Its Previously Announced Financing

Vancouver, British Columbia–(Newsfile Corp. – April 11, 2019) – STILLCANNA INC. (CSE: STIL) (FSE: 484) (“StillCanna” or the “Company”) is pleased to announce it has strengthened its Romanian operating team with the appointments of Dr. Bucur Ilie as General Manager and Ms. Georgiana Carsin as Production Manager.

Dr. Bucur Ilie holds a Ph.D. in Chemistry (Physical Chemistry) from the University of Craiova in Romania in addition to holding Graduate Degrees in Chemistry (Physical Chemistry, University of Bucharest) and Computer Science (University of Craiova). Dr. Ilie has held numerous state and private company positions including serving as General Director at the Research Center for Chemical Fertilizers, General Director at the Institute of Chemical Research and Applied Technologies, Director at Applied Systems SRL, as well as senior positions with the Environmental and Waters Management Ministry in Romania. Dr. Ilie is an accomplished university professor and researcher with publications including eight books, thirty published works, thirty research works, and fifty lectures. Dr. Ilie is an expert in laboratory research and modelling of chemical and biochemical processes.

Ms. Georgiana Carsin holds a Masters Degree in Chemistry from Polytechnic University in Bucharest with over 15-years of experience in agriculture and environmental protection. Ms. Carsin served as an environmental engineer with Agroindustriala Giubega for over five years, as an Engineer in Sanitary Engineering and Environmental Protection with Alcaruma Agro Consult Srl for over five years, and as a Research Engineer and Environmental Health Engineering with Applied Systems SRL for over five years. Ms. Carsin’s experience has been centered on environmental and process engineering within the agricultural sectors in Romania.

“We are excited to have Dr. Ilie and Ms. Carsin join our growing team in Romania,” stated Jason Dussault, President & CEO of StillCanna. “A company is only as strong as its people. Our ability to attract such high caliber individuals to our team is a testament of the foundation we are cultivating and the exciting opportunity it presents. Dr. Ilie is a highly accomplished academic and researcher with practical experience whose task is to assure we produce the highest quantity CBD possible. Ms. Carsin offers a complementary skill set with significant process engineering experience. As we ramp up to full production these experience scientists with practical knowledge simply solidifies our process.”

The Company is also pleased to announce that, further to its March 18, 2019 press release announcing a brokered private placement (the “Financing“) of subscription receipts at a price of $1.15 per subscription receipt for gross proceeds of up to $20,100,000 with the possibility of raising an additional $5,002,500 at the option of Canaccord Genuity Corp. (the “Agent“) and based on initial subscription results, it intends to complete the Financing on a fully subscribed basis. The Financing is expected to be completed on or about April 23, 2019, or such other date as mutually agreed to by the Company and the Agent, subject to the receipt of all necessary regulatory approvals, including the approval of the Canadian Securities Exchange. All securities issued pursuant to the Financing will be subject to a four-month-and-one-day hold period from the closing date, in accordance with applicable Canadian securities laws.

Each subscription receipt shall entitle the holder thereof to receive, upon satisfaction of certain escrow release conditions (including the completion of the Olimax transaction previously announced on March 18, 2019) and without payment of any additional consideration or any further action on the part of each holder thereof, one unit of StillCanna. StillCanna anticipates closing the Olimax transaction within the first half of May 2019. Each unit will consist of one common share of the company and one-half of one common share purchase warrant. Each warrant will be exercisable to acquire one common share for a period of 12 months from the date the escrow release conditions are satisfied at an exercise price of $1.73. If the escrow release conditions are not satisfied by June 30, 2019, the subscription receipts will be cancelled, and all proceeds from the brokered financing will be returned to subscribers.

ABOUT STILLCANNA INC.

StillCanna Inc. (CSE: STIL) (www.stillcanna.com) is a Canadian early-stage life sciences company focused on large-scale CBD extraction in Europe. Based on a proprietary process and intellectual property, the Company is forecasted to be one of the lowest-cost CBD extractors operating in Europe. The Company has signed an extraction contract to be the exclusive extractor for Dragonfly BioSciences LLC, a United Kingdom-based supplier of CBD. Upon the completion of the Olimax Transaction, StillCanna will be one of the leading processors and providers of market-ready CBD in Europe.

On Behalf of the Board,

Joel Leonard,
Chief Financial Officer and Director
E-mail: joel@stillcanna.com

The CSE has not in any way passed upon the merits of and has neither approved nor disapproved the contents of this news release.

Cautionary Note Regarding Forward Looking Statements: This release includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws, including statements regarding the financing being expected to be fully subscribed, the expected closing date of the financing being April 22, 2019 and that the Olimax transaction is expected to closing within the first half of May, 2019. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should” or “would” occur. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including that the financing will be fully subscribed, the financing will close as anticipated by management of the Company on April 22, 2019 and that the Olimax transaction will close as anticipated by management within the first half of May, 2019. Although the Company considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect, and the forward-looking statements in this release are subject to numerous risks, uncertainties and other factors that may cause future results to differ materially from those expressed or implied in such forward-looking statements. Such risk factors may include, among others, that the financing will not be fully subscribed, the financing will not close as anticipated by management of the Company on April 22, 2019 or at all and that the Olimax transaction will not close as anticipated by management within the first half of May, 2019 or at all. Readers are cautioned not to place undue reliance on forward-looking statements. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not intend, and expressly disclaims any intention or obligation to, update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

StillCanna Signs C$6 Million Per Month Agreement with California Based BioScience Enterprises, Inc. to Supply CBD

Vancouver, British Columbia–(Newsfile Corp. – March 28, 2019) – STILLCANNA INC. (CSE: STIL) (“StillCanna” or the “Company”) is pleased to announce that the Company has entered into a binding letter of intent with BioScience Enterprises, Inc. of California (“BioScience”) to supply C$6,000,000 of CBD isolate per month for an initial term of 6 months, such term may be extended by mutual agreement of the parties.

The Company anticipates that, subject to applicable stock exchange and regulatory approval, it will enter into a definitive agreement (the “Definitive Agreement”) with BioScience within the 60-day due diligence period under the binding letter of intent.

The Company expects to begin delivering on its contract in August of 2019 utilizing its Polish harvest of 1,500 hectares of hemp.

“We have visited BioScience Enterprises facilities,” stated Jason Dussault CEO of StillCanna. “We are impressed with their industry knowledge and capabilities. We are pleased to be a supplier of CBD isolate and hope to establish a long-standing relationship with BioScience. We believe this strategic arrangement compliments our business model and will help us reach our corporate milestones.”

Richard Parker, President of Operations, BioScience Enterprises, Inc. mentioned: “We are thrilled to be working with an innovative group like StillCanna on a partnership. Having a high standard for quality product is what makes BioScience a reputable supplier, without producers like StillCanna that wouldn’t be possible.”

ABOUT BIOSCIENCE ENTERPRISES, INC.

Since its inception in 2018 – Bioscience has emerged as a leading contract manufacturer and supplier of CBD nationwide. The company native to California has contracts across the continental USA and Canada for the supply of EU and domestic high-grade isolate, distillate and a variant of finished products. The company is housed in a secure 18,000 square foot plant, which is capable of a monthly output of 1.5 million glass tinctures, 2 million vape PET products, 1.5 million cartridges and 1.5 million disposable pens. BioScience supplies for many of America’s known brands and supplies bulk CBD to various industry manufacturing companies. The company intends to apply through the United States DEA for their own license to import hemp-derived CBD from around the world. BioScience strives to maintain its purest CBD supply on the market through a world-class quality assessment and quarantine process. BioScience currently estimates to contract over 100mm in gross sales through 2019.

For more information, please visit www.bioscience-enterprises.com

ABOUT STILLCANNA INC.

StillCanna Inc. (CSE: STIL) (www.StillCanna.com) is a Canadian early-stage life sciences company focused on large-scale CBD extraction in Europe. Based on a proprietary process and intellectual property, the Company is forecasted to be one of the lowest-cost CBD extractors operating in Europe. The Company has signed an extraction contract to be the exclusive extractor for Dragonfly BioSciences LLC, a United Kingdom-based supplier of CBD. Upon the completion of the Olimax Transaction, StillCanna is anticipated to be one of the largest processors and providers of market-ready CBD in Europe.

For more information, please visit www.StillCanna.com

On Behalf of the Board,
Joel Leonard,
Chief Financial Officer and Director
E-mail: accounting@jclpartners.ca

The CSE has not in any way passed upon the merits of and has neither approved nor disapproved the contents of this news release.

Cautionary Note Regarding Forward Looking Statements: This release includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws, including statements regarding the expectation of the Company entering into the Definitive Agreement by the expiry of the due diligence period and the terms of the Definitive Agreement are expected to reflect the binding letter of intent as anticipated by management. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should” or “would” occur. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including that the Company will be able to enter into the Definitive Agreement by the expiry of the due diligence period and that the Definitive Agreement will reflect the terms of the binding letter of intent as anticipated by management. Although the Company considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect, and the forward-looking statements in this release are subject to numerous risks, uncertainties and other factors that may cause future results to differ materially from those expressed or implied in such forward-looking statements. Such risk factors may include, among others, that the Company will not be able to enter into the Definitive Agreement by the expiry of the due diligence period, that the LOI will be terminated and that the anticipated CBD purchase will not be completed and that the Company may not supply CBD isolate to BioScience on the terms as anticipated by management. Readers are cautioned not to place undue reliance on forward-looking statements. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not intend, and expressly disclaims any intention or obligation to, update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

StillCanna Signs Definitive Agreement for the Acquisition of a Leading European Hemp Cultivator Olimax

March 18, 2019 – Vancouver, British Columbia – StillCanna Inc. (CSE: STIL) (“StillCanna” or the “Company”) is pleased to announce that today, March 18th, 2019, the Company signed of a definitive agreement to complete the acquisition of Olimax NT SP. Z .O.O (“Olimax”), a fully-licensed, privately-owned, vertically-integrated cultivator and producer of cannabidiol (“CBD”) in Poland, for total consideration consisting of 24 million common shares of StillCanna at a deemed per share price of C$1.15 and a cash payment of C$2 million (the “Olimax Transaction”).

StillCanna, a European-focused CBD producer with operations in Romania will acquire Olimax as a means to further its strategy of providing large quantities of high-quality CBD extracts to the European and global markets. The Olimax Transaction provides StillCanna with a vertically-integrated and licensed cultivator, extractor and formulator of CBD. Olimax’s core strength is in agriculture, with over 20-years of experience in farming hemp, in addition to having a fully-developed product line and a proprietary, European Union (“EU”) certified, high-CBD content hemp varietal. Olimax successfully cultivated and harvested hemp from over 600 hectares in 2018.

Jason Dussault, Chief Executive Officer of StillCanna commented, “It is rare when the core competencies of two companies complement each other so well. Olimax’s agricultural experience matched with our extraction expertise creates the perfect storm. The combined company will have the capacity to produce 16 million grams of high-potency CBD for the European and global market in 2019.  We estimate that with a further investment of C$10 million for land lease, planting and harvesting we expect to expand to over 60 million grams by 2021.”

TRANSACTION RATIONALE

  • The transaction bolsters StillCanna’s pro-forma production profile to 16 million grams of CBD in 2019, with potential to grow to 32 million grams in 2020 and over 60 million grams in 2021.
  • The addition of Olimax’s two founders, with their extensive 20-year history and academic background, provides StillCanna with significant internal cultivation expertise.
  • Improves alignment of management as Olimax’s founders would hold 29% of the pro-forma company (20 million shares subject to a 36-month escrow).

TERMS OF THE TRANSACTION

Under the terms of the Olimax Transaction, StillCanna will acquire all the issued and outstanding shares of Olimax from the arm’s length shareholders of Olimax for total consideration consisting of 24 million common shares of StillCanna and a cash payment of C$2.0 million. Following the acquisition, Olimax will become a wholly-owned subsidiary of StillCanna. Subject to completion of the Olimax Transaction and the Brokered Financing, StillCanna plans to invest up to C$12.0 million to expand Olimax’s capacity in agriculture, associated infrastructure, and working capital. Additionally, StillCanna has secured the services of the Olimax founders for a period of a minimum of three years to aid with the anticipated expansion of the business in Poland and throughout the EU. The Olimax Transaction is subject to customary conditions, including regulatory and exchange approval, due diligence, and StillCanna closing the Brokered Financing. The Olimax Transaction is expected to close shortly after satisfaction of all outstanding conditions under the Definitive Agreement, which closing date is expected to occur in the second quarter of 2019.

PRIVATE PLACEMENT FINANCING

StillCanna is also pleased to announce that it has entered into an  agreement with Canaccord Genuity Corp. (the “Agent”) to raise, on a commercially reasonable efforts private placement basis up to 17,400,000 subscription receipts (the “Subscription Receipts”) at a price of C$1.15 per Subscription Receipt (the “Issue Price”) for aggregate gross proceeds of up to C$20,010,000 (the “Brokered Financing”). In addition, the Company has granted the Agent an option to increase the size of the Brokered Financing by up to 4,350,000 Subscription Receipts for additional gross proceeds of C$5,002,500, exercisable in whole or in part at any time prior to the closing of the Brokered Financing, for aggregate gross proceeds of up to C$25,012,500.

Each Subscription Receipt shall entitle the holder thereof to receive, upon satisfaction of certain escrow release conditions (including the completion of the Olimax Transaction) and without payment of any additional consideration or any further action on the part of each holder thereof, one unit of StillCanna (a “Unit”). Each Unit will consist of one common share of the Company (a “Common Share”) and one-half of one common share purchase warrant (each whole warrant, a “Warrant”).  Each Warrant will be exercisable to acquire one Common Share for a period of 12-months from the date the escrow release conditions are satisfied at an exercise price of C$1.73. If the escrow release conditions are not satisfied by June 30, 2019, the Subscription Receipts will be canceled and all proceeds from the Brokered Financing will be returned to subscribers.

The Company intends to use the net proceeds of the Brokered Financing to expand CBD processing capacity at the Company’s facility in Romania, to build out Olimax’s CBD extraction facility and agricultural capabilities, along with working capital and general corporate expenditures.

The Agent will be paid a cash commission equal to 7.0% of the gross proceeds of the Brokered Financing and will also receive warrants (the “Compensation Warrants”) to acquire that number of Units which is equal to 7.0% of the aggregate number of Subscription Receipts sold under the Brokered Financing. Each Compensation Warrant will be exercisable at the Issue Price for a period of 12-months following the date the Escrow Release Conditions are satisfied.

The Brokered Financing is expected to be completed on April 11th, 2019 (the “Closing Date”), or such other date as mutually agreed to by the Company and the Agent, subject to the receipt of all necessary regulatory approvals, including the approval of the Canadian Securities Exchange. All securities issued pursuant to the Brokered Financing will be subject to a four month and one day hold period from the Closing Date, in accordance with applicable Canadian securities laws.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “US Securities Act”) or any state securities laws and may not be offered or sold in the United States or to or for the account or benefit of US persons unless registered under the US Securities Act and applicable state securities laws or an pursuant to an exemption from such registration as available.

For more information, please visit www.StillCanna.com

On Behalf of the Board,

Joel Leonard,
Chief Financial Officer and Director
E-mail: joel@stillcanna.com
Phone: 778-838-3692

ABOUT OLIMAX

Olimax is a fully integrated and licensed cultivator, extractor and formulator of CBD in Poland with operations spanning over 20 years. Having recently successfully cultivated and harvested over 600 hectares of hemp, they intend to expand their agricultural footprint to over 5,000 hectares by 2021. Olimax has registered a high-potency CBD hemp varietal with the EU and holds rights to proprietary harvesting and processing equipment and techniques. In addition to being experienced in agriculture, Olimax has also formulated a large number of CBD and hemp-based products which span from CBD oils and hemp protein to cosmetics and beverages.  Through significant experience and industry connections, Olimax has established itself as a leader in hemp cultivation and processing throughout Europe. The company has more recently focused on cultivating an extensive bank of seeds from their proprietary and registered Glyana strain.  This seed bank gives the company the freedom to significantly and independently expand its cultivation holdings.  Olimax’s founders have over 20 years of experience in growing and formulating CBD products, are widely considered agricultural experts in their field and hold degrees in chemistry and physics.  The combination of education, practical experience and a true passion for the hemp plant has propelled them to be true leaders in their field and widely respected throughout the European hemp industry.

ABOUT STILLCANNA INC.

StillCanna Inc. (CSE: STIL) (www.stillcanna.com) is a Canadian early-stage life sciences company focused on large-scale CBD extraction in Europe.  Based on a proprietary process and intellectual property, the Company is forecasted to be one of the lowest-cost CBD extractors operating in Europe. The company has signed an extraction contract to be the exclusive extractor for Dragonfly BioSciences LLC, a United Kingdom-based supplier of CBD. Upon the completion of the Olimax Transaction, StillCanna will be one of the leading processors and providers of market-ready CBD in Europe.

EVI Global Group Developments Corp. (CSE: EVI) Changes to StillCanna Inc. (CSE: STIL), a Leading Extractor of CBD in Europe, and Begins Resumption of Trading

VANCOUVER, British Columbia, STILLCANNA INC. (FORMERLY EVI GLOBAL GROUP DEVELOPMENTS CORP.) (CSE: STIL) (“StillCanna” or the “Company”) is pleased to announce the Company has completed a change of business from a mining issuer to a life sciences issuer. The Company received approval from its shareholders for the Change of Business and has received approval from the Canadian Securities Exchange (the “CSE“) to resume trading. StillCanna intends to be a leading extractor of CBD in Europe in 2019.

In connection with the Change of Business, the Company also announces that, effective March 15, 2019, it has changed its name from “EVI Global Group Developments Corp.” to “StillCanna Inc.” Trading of the Company’s common shares will resume under the new name and under the new ticker symbol “STIL” as of market open March 15, 2019. The new CUSIP will be 86071P107 and the new ISIN number will be CA86071P1071.

The Company is also pleased to announce it has closed its previously announced Definitive Share Exchange Agreement with Borganic Consulting Inc. (“Borganic“) dated October 15, 2018, in which the Company acquired all the issued and outstanding shares of Borganic, being 13,098 common shares, in exchange for 15,000,000 common shares of the Company (the “Transaction“). Following the closing of the Transaction, the Company had 57,943,000 common shares of the Company issued and outstanding.

Upon closing of the Transaction on February 26, 2019, Shae De Jaray was appointed Chief Technical Officer of the Company and Marc Crimeni was appointed a director of the Company.

“We’ve come a long way in a short time”, pointed out Jason Dussault, CEO of StillCanna.  “Completing our first acquisition and resuming trading are great milestones for the Company. All of our required extraction equipment is on site at our European facility. To enhance shareholder value, we continue to look at various acquisition opportunities globally.”

In connection with the Transaction, the Company also issued 1,800,000 common shares to certain finders. It also issued 2,000,000 common shares to certain consultants in exchange for financial advisory services.

About StillCanna Inc.

StillCanna Inc. (CSE: STIL) www.stillcanna.com is a Canadian early-stage life sciences company focused on large scale CBD extraction in Europe.  The Company feels its proprietary intellectual property allows it to extract CBD at a lower cost. The Company has signed an initial extraction contract in Europe to be the exclusive extractor for Dragonfly BioSciences LLC, a UK based supplier of CBD. The Company continues to look for other industry acquisitions that will enhance shareholder value.

For further information please contact:
Joel Leonard, CFO, Director, StillCanna Inc.
E-mail: joel@stillcanna.com
Phone: (778) 838-3692

 

This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.

EVI’s European Based Extraction Facility Initiates Hemp Processing

Vancouver, British Columbia–(Newsfile Corp. – February 19, 2019) – EVI GLOBAL GROUP DEVELOPMENTS CORP. (CSE: EVI) (“EVI” or the “Company) is proud to announce it has begun the initial processing of hemp in its European based extraction facility.

The first step in extraction of CBD from industrial hemp is to take the whole plant and separate the seeds, leaves, stalks and flowers prior to the CBD extraction process. Only the flowers from the hemp plant are used to extract CBD. The Company has begun the separation process, stockpiling CBD rich flower for extraction. The facility is expected to have the capability to process over 1,000,000 pounds of hemp annually.

The facility has been designed to meet EU GMP certification. It is expected to have the capability of extracting up to 3,000 pounds of flower daily, making it the largest processor of finished market ready CBD molecules in Europe.

“As the global cannabis business matures through 2019 the necessity for efficient, scalable and professional cannabis extraction has become abundantly clear. Companies that can rise to the highest standards of extraction will likely have an advantage in 2019 and beyond,” commented Jason Dussault, CEO of EVI.

“Almost weekly, one of our esteemed industry colleagues announces they’re breaking ground on a large extraction facility that is still 12 to 18 months out. Our founders have been extracting cannabinoids for over five years and their knowledge and vision has given us first mover advantage in Europe.”

“Our engineering staff’s attention to detail, operating procedures, customized equipment and implementation has resulted in a unique extraction facility that is deploying an efficient extraction system unlike any other facility. I couldn’t be more proud of our team.”

As the Company completes the final steps of equipment placement and testing, it is expected to continue to process its hemp inventory in preparation for extraction.

For pictures, videos and more updates please visit The Stillcanna Report at www.thestillcannareport.com

For further information please contact: Jason Dussault, CEO, Director, EVI Global Group Developments Corp. E-mail: jason@stillcanna.com